News

The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
NJ drug companies will spend billions to expand in the U.S. Here's what's driving them
Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, health care analysts say.
Cassidy argues allowing drug companies to profit helps medical industry discover new cures
Cassidy’s comments come after Trump signed an executive order to make prescription drug prices in the United States ...
Can this under-the-radar company cash in on the $150 bn weight-loss drug boom?
Onesource Specialty, a newly demerged pharma CDMO, is set to benefit from the $150 billion GLP-1 weight-loss drug boom with ...
Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade)
Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...
Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million
Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug ...
STAT13h
A rare disease drug is rejected, even as the FDA talks about new approval pathway
Instead of approving Stealth BioTherapeutics' drug for Barth syndrome, the FDA withheld its endorsement, but decided it may ...
Oregon lawmakers side with safety-net hospitals in discount drug battle
A federal program allows nonprofit hospitals and clinics to buy prescription drugs at steep discounts, charge insurers full ...
Some Michigan hospitals marking up drug prices by up to 800%, report finds
Some Michigan hospitals are marking up prices by thousands of dollars above what they pay manufacturers for certain prescription drugs, according to a new report from the Michigan Health Purchasers ...